<DOC>
	<DOCNO>NCT02048540</DOCNO>
	<brief_summary>Background Local advance gastric carcinoma ( LAGC ) suggest potentially cure R0 resection , neoadjuvant chemotherapy increase R0 resection rate enough . Bevacizumab ( Bev ) , anti-tumor angiogenesis monoclonal antibody , combine chemotherapy show effective advanced GC . In addition , CTC suggest indicator anti-tumor drug ' efficacy . Therefore , study , investigator plan evaluate efficacy safety neoadjuvant Bev plus docetaxel/oxaliplatin/5-FU/CF ( DOF ) versus DOF mainly gastric antrum LAGC , investigate whether CTC effectiveness indicator . Methods 86 patient diagnose IIIb-IIIc GC enrol randomly assign ( 1:1 ) receive neoadjuvant Bev ( 5 mg/kg , d1 ) plus DOF ( docetaxel , 75 mg/m2 , iv , d1 ; oxaliplatin , 85 mg/m2 , iv , d1 ; 5-FU , iv infusion 600 mg/m2 iv injection 400mg/m2 , d1-2 ; CF , 200 mg/m2 , d1 d2 ) DOF 3-week , 2-4 cycle preoperation , another 2-4 cycle postoperation total 6 cycle . The primary endpoint R0 resection rate . CTC detect every 8 week . All patient sign informed consent .</brief_summary>
	<brief_title>Neoadjuvant Bev Plus DOF v DOF LAGC Its Association With Circulating Tumor Cell</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically confirm locally advanced adenocarcinoma stomach . Age 18 70 , Karnofsky score high 80 . T34，N13，M0 ( AJCC 7th ) , potentially resectable . No severe functional damage major organ , normal blood cell , normal liver kidney function . Clinical finding distant metastasis Peritoneal carcinomatosis Prior systemic ( chemo target ) treatment . Prior radiotherapy upper abdomen Previous malignancy within 5 year , exception adequately treat cervical carcinoma situ localize nonmelanoma skin cancer Upper gastrointestinal bleeding Any contraindication treatment docetaxel , 5fu oxaliplatin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>